What's new

Human medicines European public assessment report (EPAR): Supemtek Tetra (previously Supemtek), Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Supemtek Tetra (previously Supemtek), Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 7, Status: Authorised

Mar 7, 2025 - 13:33
 0
Human medicines European public assessment report (EPAR): Supemtek Tetra (previously Supemtek), Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Supemtek Tetra (previously Supemtek), Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 7, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Truqap, capivasertib, ...

Next Article

EMEA-003466-PIP01-23

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Lutathera, lutetium (177Lu) oxodotreotide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0461/2023

Opinion/decision on a Paediatric investigation plan (PI...

Mar 6, 2025  0

Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 24, 2025  0

Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0